 |
|
Metoclopramide-Associated Tardive DyskinesiaAn Analysis of 67 Cases
Daniel D. Sewell, MD;
Dilip V. Jeste, MD
Arch Fam Med. 1992;1(2):271-278.
References
Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.
| |
1. Baldessarini RJ, Cole JO, Davis JM, et al. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1980:23.
2. Perry PJ, Alexander B, Liskow Bl. Psychotropic Drug Handbook. 5th ed. Cincinnati, Ohio: Harvey Whitney Books; 1988:28. 3. Jeste DV, Yassa R. Neuroleptic-induced tardive dyskinesia. In: Francis A, ed. DSM-IV Sourcebook. Washington, DC: American Psychiatric Association. In press. 4. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 1982;39:473-481.
FREE FULL TEXT
5. Jeste DV, Wyatt RJ. Understanding and Treating Tardive Dyskinesia. New York, NY: Guilford Press; 1982. 6. Jeste DV, Lohr JB, Clark K, Wyatt RJ. Pharmacologic treatment of tardive dyskinesia in the 1980s. J Clin Psychopharmacol. 1988;8(suppl):38-48.
PUBMED
7. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology. 1988;38:391-394.
FREE FULL TEXT
8. Tancredi LR. Malpractice and tardive dyskinesia: a conceptual dilemma. J Clin Psychopharmacol. 1988;8(suppl):71-76.
PUBMED
9. Casteels-Van Daele M, Jaelen J, Van Der Schueren P, Zimmerman A, Van Den Bon P. Dystonic reactions in children caused by metoclopramide. Arch Dis Child. 1970;45:130-133.
FREE FULL TEXT
10. Robinson OPW. Metoclopramide: side effects and safety. Postgrad Med J. 1973;49(suppl):77-80.
FREE FULL TEXT
11. Board AW. Tardive dyskinesia associated with high-dose intravenous metoclopramide. N Engl J Med. 1986;315:518-519.
PUBMED
12. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature. 1979;277-93-96.
PUBMED
13. Alander T, Anden N, Grabowska-Anden M. Metoclopramide and sulpiride as selecting blocking agents of pre- and postsynaptic dopamine receptors. Naunyn Schmiedebergs Arch Phamacol. 1980;312:145-150.
14. Harrington RA, Hamilton CW, Brogden RN, Linkewich RA, Romankiewicz, Heel RC. Metoclopramide: an updated review of its pharmacologic properties and clinical use. Drug Eval. 1983;25:451-494.
15. Schutz E. Fortechritte in der Therapie des Ulcus duodeni. Munch Med Wochenschr. 1976;118:231-234.
16. Borenstein PP, Bles G. Effets cliniques et electroencephalographiques du metoclopramide en psychiatrie. Therapie. 1965;20:975-995.
PUBMED
17. Nakra BRS, Bond AJ, Lader MH. Comparative psychotropic effects of metoclopramide and prochlorpromazine in normal subjects. J Clin Pharmacol. 1975;15:449-454.
PUBMED
18. Stanley M, Wilk S. Striatal DOPAC elevation predicts antipsychotic efficacy of metoclopramide. Life Sci. 1979;24:1907-1912.
PUBMED
19. Stanley M, Lautin A, Rotrosen J, Gershon S. Antipsychotic efficacy of metoclopramide: do DA/neuroleptic receptors mediate the action of antipsychotic drugs? IRCS Med Sci Clin Med Clin Pharmacol Nervous Sys Psychol Psychiatry. 1979;7:332.
20. Stanley M, Lautin A, Rotrosen J, Gershon S, Kleinberg D. Metoclopramide: antipsychotic efficacy of a drug lacking potency in receptor models. Psychopharmacology. 1980;71:219-225.
PUBMED
21. Borda IT. Drug treatment of gastrointestinal disorders. In: Swift CG, ed. Clinical Pharmacology in the Elderly. New York, NY: Marcel Dekker Inc; 1987:529-579. 22. Craig JB, Powell BL, White DR, Capizzi RL. Antiemetic therapy in patients treated with high-dose cytosine. Oncology. 1987;44:90-92.
PUBMED
23. Physicians' Desk Reference, 45th Edition. Oradell, NJ: Medical Economics Books; 1991. 24. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. BMJ. 1985;291:930-932.
FREE FULL TEXT
25. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:488-489.
FREE FULL TEXT
26. Beauclair L, Fontaine R. Tardive dyskinesia associated with metoclopramide. Can Med Assoc J. 1986;134:613-614.
PUBMED
27. Melmed S, Bank H. Metoclopramide and facial dyskinesia. BMJ. 1975;8:331.
28. Indo T, Ando K. Metoclopramide-induced parkinsonism: clinical characteristics of ten cases. Arch Neurol. 1982;39:494-496.
FREE FULL TEXT
29. Leopold NA. Prolonged metoclopramide-induced dyskinetic reaction. Neurology. 1984;34:238-239.
FREE FULL TEXT
30. Jankovic J, Glass JP. Metoclopramide-induced phantom dyskinesia. Neurology. 1985;35:432-435.
FREE FULL TEXT
31. Miller LG, Jankovic J. Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J. 1990;83:525-532.
PUBMED
32. Grimes JD, Hassan MN, Krelina M. Long-term follow-up of tardive dyskinesia due to metoclopramide. Lancet. 1982;2:563.
PUBMED
33. Miller LG, Jankovic J. Metoclopramide-induced movement disorders: clinical findings with a review of the literature. Arch Intern Med. 1989;149:2486-2492.
FREE FULL TEXT
34. Patel M, Louis S. Long-term neurologic complications of metoclopramide. N Y State J Med. 1986;86:210.
PUBMED
35. Yamamoto M, Ujike H, Ogawa N. Metoclopramide-induced parkinsonism. Clin Neuropharmacol. 1987;10:287-289.
PUBMED
36. Sewell DD, Yoshinobu BH, Caligiuri MP, Jeste DV. Metoclopramide-associated tardive dyskinesia in hemodialysis patients with diabetes mellitus: two case reports. Gen Hosp Psychiatry. In press. 37. Wiholm BE, Mortimer 0, Boethius G, Haggstrom JE. Tardive dyskinesia associated with metoclopramide. BMJ. 1984;288:545-547.
FREE FULL TEXT
38. Ganzini L, Casey DE, Hoffman WF, Heintz RT. Tardive dyskinesia in neuroleptic-treated diabetics. Presented at the 30th Annual Meeting of the American College of Neuropsychopharmacology; December 10, 1991; San Juan, Puerto Rico. 39. Casey DE. Tardive dyskinesia and affective disorders. In: Gardos G, Casey DE, eds. Tardive Dyskinesia and Affective Disorders. Washington, DC: American Psychiatric Association; 1984:1-20. 40. Shearer RM, Bownes IT, Curran P. Tardive akathisia and agitated depression during metoclopramide therapy. Ada Psychiatr Scand. 1984;70:428-431.
41. Breitbart W. Tardive dyskinesia associated with high-dose intravenous metoclopramide. N Engl J Med. 1986;315:518.
PUBMED
42. Samie MR, Dannenhoffer MA, Rozek S. Life-threatening tardive dyskinesia caused by metoclopramide. Mov Disord. 1987;2:125-129.
PUBMED
43. Kataria M, Traub M, Marsden CD. Extrapyramidal side-effects of metoclopramide. Lancet. 1978;2:1254-1255.
PUBMED
44. Lang AE. Clinical differences between metoclopramide- and antipsychotic-induced tardive dyskinesia. Can J Neurol Sci. 1990;17:137-139.
PUBMED
45. Sirota RA, Kimmel PL, Trichtinger MA, Diamond BF, Stein HD, Yudis M. Metoclopramide-induced parkinsonism in hemodialysis patients: report of two cases. Arch Intern Med. 1986;146:2070-2071.
FREE FULL TEXT
46. Casey DE, Hansen TE. Spontaneous dyskinesias. In: Jeste DV, Wyatt RJ, eds. Neuropsychiatric Movement Disorders. Washington, DC: American Psychiatric Association; 1984:67-95. 47. Casey DE. Tardive dyskinesia. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:1411-1419. 48. Jeste DV, Wyatt RJ. Changing epidemiology of tardive dyskinesia: an overview. Am J Psychiatry. 1981;138:297-309.
FREE FULL TEXT
49. Lavy S, Melamed E, Penchas S. Tardive dyskinesia associated with metoclopramide. BMJ. 1978;1:77-78.
FREE FULL TEXT
50. Lazzara RR, Stoudemire A, Manning D, Prewitt KC. Metoclopramide-induced tardive dyskinesia: a case report. Gen Hosp Psychiatry. 1986;8:107-109.
PUBMED
51. Grimes JD, Hassan MN, Preston DN. Adverse neurologic effects of metoclopramide. Can Med Assoc J. 1982;126:23-25.
ABSTRACT
52. Casey DE. Metoclopramide side effects. Ann Intern Med. 1983;98:673-674.
PUBMED
53. Kane JM, Woerner M, Lieberman J, Kinon B. Tardive dyskinesia. In: Jeste DV, Wyatt RJ, eds. Neuropsychiatric Movement Disorders. Washington, DC: American Psychiatric Association; 1984:97-118. 54. Hoffman WF, Labe SM, Casey DE. Neurolepticinduced parkinsonism in older schizophrenics. Biol Psychiatry. 1987;22:427-439.
PUBMED
55. Gardos G, Perenyi A, Cole JO, Samu I, Kocsis E, Casey DE. Seven-year follow-up of tardive dyskinesia in Hungarian outpatients. Neuropsychopharmacology. 1988;1:169-172.
PUBMED
56. Crane GE. Pseudoparkinsonism and tardive dyskinesia. Arch Neurol. 1972;27:426-430.
FREE FULL TEXT
57. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharm. 1988;8(suppl):52-56.
58. Ganzini L, Heintz RT, Hoffman WF, Casey DE. The prevalence of tardive dyskinesia in neuroleptictreated diabetics: a controlled study. Arch Gen Psychiatry. 1991;48:259-263.
FREE FULL TEXT
|
